UPMC Hillman Cancer Center

Running trials

• Recruiting

  Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma

  NCT07619521· Phase 1/2· National Cancer Institute (NCI)· Source

• Recruiting

  Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma

  NCT07156227· Phase 1· National Cancer Institute (NCI)· Source

• Not yet recruiting

  Neoadjuvant RP2 + Nivolumab in Patients With Melanoma

  NCT07862530· Phase 2· Yana Najjar· Source

• Not yet recruiting

  Identifying Mediators of Exercise-induced Tumor Microenvironment Remodeling to Enhance Primary Chemotherapy Response (IMPROVE-Ovarian)

  NCT07932106· University of Pittsburgh· Source

• Recruiting

  Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma

  NCT07631325· Phase 1/2· John Kirkwood· Source

• Not yet recruiting

  Circulating Tumor DNA-Informed Adjuvant Therapy for Intermediate-Risk Head and Neck Cancer

  NCT07932067· Phase 2· Kevin Contrera· Source

• Recruiting

  A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

  NCT07293247· Phase 2· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

  NCT07520006· Phase 1/2· Nurix Therapeutics, Inc.· Source

• Recruiting

  SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors

  NCT07812805· Phase 1· SK Life Science, Inc.· Source

• Recruiting

  Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

  NCT07003295· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

  NCT07215910· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

  NCT07012031· Phase 1/2· National Cancer Institute (NCI)· Source

• Recruiting

  Investigating Real-Time Immunotherapy Symptoms Study

  NCT07280715· University of Pittsburgh· Source

• Recruiting

  A Phase 1 Study of the Safety and Tolerability of CTX-10726

  NCT07419841· Phase 1· Compass Therapeutics· Source

• Recruiting

  Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

  NCT06980038· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

  NCT07061951· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

  NCT07326566· Phase 2· Black Diamond Therapeutics, Inc.· Source

• Recruiting

  Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

  NCT07493512· Phase 1· Amgen· Source

• Recruiting

  Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

  NCT07195734· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

  NCT07271667· Phase 2· Curis, Inc.· Source

• Recruiting

  ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

  NCT07342478· Phase 3· Newave Pharmaceutical Inc· Source

• Recruiting

  Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

  NCT07068074· Phase 3· ECOG-ACRIN Cancer Research Group· Source

• Enrolling by invitation

  Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia

  NCT06773936· Phase 2· SWOG Cancer Research Network· Source

• Recruiting

  Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer

  NCT07057791· Phase 2· PrECOG, LLC.· Source

• Recruiting

  A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)

  NCT07405151· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

  NCT07221149· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

  NCT07491497· Phase 1/2· TRIANA Biomedicines, Inc.· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

  NCT07284849· Phase 3· Incyte Corporation· Source

• Recruiting

  Sulforaphane for the Prevention of Melanoma in Patients With Multiple Atypical Nevi and a Prior History of Melanoma

  NCT07040280· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Recruiting

  Distance-Based Exercise to Preserve Function and Prevent Disability

  NCT07059884· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

  NCT07397338· Phase 1/2· Revolution Medicines, Inc.· Source

• Recruiting

  Neoadjuvant Darovasertib in Primary Uveal Melanoma

  NCT07015190· Phase 3· IDEAYA Biosciences· Source

• Recruiting

  A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

  NCT07235293· Phase 2· Kahr Bio Australia Pty Ltd· Source

• Recruiting

  Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

  NCT07315113· Phase 1· Nuvectis Pharma, Inc.· Source

• Recruiting

  Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

  NCT07252232· Phase 3· Revolution Medicines, Inc.· Source

• Recruiting

  A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

  NCT06524544· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  Impact of Circadian Rhythm on Immunotherapy

  NCT07224971· Phase 2· Liza Villaruz, MD· Source

• Recruiting

  Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)

  NCT07281430· National Cancer Institute (NCI)· Source

• Recruiting

  Tongue-out Radiation Therapy (TORT) for the Mitigation of Radiotherapy-related Toxicities in Patients With Head and Neck Cancer

  NCT07227792· Yvonne Mowery· Source

• Recruiting

  Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma

  NCT07223411· John Kirkwood· Source

• Recruiting

  Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial

  NCT06811116· Phase 1/2· National Cancer Institute (NCI)· Source

• Recruiting

  Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

  NCT07223424· Phase 2· Diwakar Davar· Source

• Recruiting

  Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

  NCT07001748· Phase 2/3· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

  NCT07076121· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

  NCT07221500· Phase 2· Nurix Therapeutics, Inc.· Source

• Active, not recruiting

  Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

  NCT07140900· Phase 1· Amgen· Source

• Recruiting

  Circulating Tumor DNA in High Risk Localized Prostate Cancer

  NCT07222436· University of Pittsburgh· Source

• Active, not recruiting

  CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer

  NCT06730100· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer

  NCT06868485· Phase 2· Wayshine Biopharm, Inc.· Source

• Recruiting

  Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

  NCT06070012· Phase 2· Diwakar Davar· Source

Showing 50 of 364.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer37 recruiting
• Head and neck cancer25 recruiting
• Melanoma25 recruiting
• Colorectal cancer19 recruiting
• Gastric and oesophageal cancer16 recruiting
• Kidney cancer15 recruiting
• Ovarian cancer14 recruiting
• Bladder cancer13 recruiting
• Childhood cancers12 recruiting
• Prostate cancer12 recruiting
• Liver and biliary tract cancer10 recruiting
• Endometrial cancer8 recruiting
• Acute myeloid leukaemia7 recruiting
• Pancreatic cancer7 recruiting
• Chronic lymphocytic leukaemia5 recruiting
• Metastatic breast cancer5 recruiting
• Sarcoma5 recruiting
• Cervical cancer4 recruiting
• Glioblastoma4 recruiting
• Myelodysplastic syndromes4 recruiting
• Myeloproliferative neoplasms3 recruiting
• Neuroendocrine tumours3 recruiting
• Triple-negative breast cancer3 recruiting
• Mesothelioma2 recruiting
• Ulcerative colitis2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Crohn's disease1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Lupus (SLE)1 recruiting
• Mantle cell lymphoma1 recruiting
• Meningioma1 recruiting
• Multiple sclerosis1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Rheumatoid arthritis1 recruiting
• Sickle cell disease1 recruiting
• Sjögren's disease1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Thyroid cancer1 recruiting

Closed trials

• Withdrawn

  Bacterial Decolonization Plus Intraoperative Angiography for Soft Tissue Sarcomas Receiving Preoperative Radiotherapy (CONCERTO)

  NCT06712433· Phase 2· Adam Olson· Source

• Terminated

  A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers

  NCT06523803· Phase 1· Zymeworks BC Inc.· Source

• Terminated

  Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

  NCT05554354· Phase 2· National Cancer Institute (NCI)· Source

• Terminated

  Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

  NCT06006923· Phase 2· Anwaar Saeed· Source

• Recruiting

  A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

  NCT06228326· Phase 1/2· Krystal Biotech, Inc.· Source

• Recruiting

  A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer

  NCT06095505· Phase 2· Puma Biotechnology, Inc.· Source

• Terminated

  Study of IK-595 in RAS- or RAF-altered Advanced Tumors

  NCT06270082· Phase 1· Ikena Oncology· Source

• Terminated

  Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

  NCT05712694· Phase 3· Polaris Group· Source

• Recruiting

  A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

  NCT05920356· Phase 3· Amgen· Source

• Recruiting

  A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

  NCT06022029· Phase 1· OncoNano Medicine, Inc.· Source

• Completed

  Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

  NCT06036836· Phase 2· Merck Sharp & Dohme LLC· Source

• Terminated

  Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases

  NCT05746481· Phase 2· Liza Villaruz, MD· Source

• Completed

  A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

  NCT05753722· Phase 1· Incendia Therapeutics· Source

• Recruiting

  ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

  NCT05580562· Phase 3· Jazz Pharmaceuticals· Source

• Completed

  Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

  NCT05585034· Phase 1· Xencor, Inc.· Source

• Terminated

  GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

  NCT05130255· Phase 1· Y-mAbs Therapeutics· Source

• Completed

  A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

  NCT05508867· Phase 2· Merck Sharp & Dohme LLC· Source

• Withdrawn

  Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer

  NCT05364645· Phase 2· SWOG Cancer Research Network· Source

• Terminated

  Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

  NCT07121829· Phase 1· Day One Biopharmaceuticals, Inc.· Source

• Completed

  A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

  NCT05293496· Phase 1· MacroGenics· Source

• Completed

  A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer

  NCT05171777· Phase 2· Hoffmann-La Roche· Source

• Terminated

  A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)

  NCT05267470· Phase 1· Amgen· Source

• Terminated

  Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

  NCT05275439· Phase 1· Shattuck Labs, Inc.· Source

• Recruiting

  Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

  NCT05098132· Phase 1/2· Synthekine· Source

• Completed

  Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)

  NCT05061017· Phase 2· Diwakar Davar· Source

• Completed

  Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

  NCT04997902· Phase 1/2· Kura Oncology, Inc.· Source

• Terminated

  Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer

  NCT04982224· Phase 1· Regeneron Pharmaceuticals· Source

• Completed

  XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

  NCT05005728· Phase 2· Xencor, Inc.· Source

• Terminated

  Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma

  NCT04688658· Phase 1/2· John Kirkwood· Source

• Completed

  Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)

  NCT04924101· Phase 2· Merck Sharp & Dohme LLC· Source

• Terminated

  A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors

  NCT04875806· Phase 1/2· NextCure, Inc.· Source

• Terminated

  A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma

  NCT04996004· Phase 2· Pfizer· Source

• Completed

  XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer

  NCT04825288· Phase 1/2· XBiotech, Inc.· Source

• Terminated

  To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

  NCT04551053· Phase 3· Incyte Corporation· Source

• Terminated

  CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma

  NCT04695977· Phase 2/3· Regeneron Pharmaceuticals· Source

• Terminated

  CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  NCT04633278· Phase 2· Regeneron Pharmaceuticals· Source

• Completed

  Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma

  NCT04493203· Phase 2· Yana Najjar· Source

• Completed

  Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

  NCT04626518· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Completed

  Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

  NCT04626479· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Completed

  A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1

  NCT03776071· Phase 3· Denovo Biopharma LLC· Source

• Completed

  The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC

  NCT04338399· Phase 3· Adlai Nortye Biopharma Co., Ltd.· Source

• Completed

  Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

  NCT04471844· NovoCure Ltd.· Source

• Withdrawn

  Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

  NCT04607772· Phase 1/2· Karyopharm Therapeutics Inc· Source

• Completed

  A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)

  NCT04489888· Phase 4· Merck Sharp & Dohme LLC· Source

• Completed

  Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

  NCT04472598· Phase 3· AbbVie· Source

• Completed

  Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab

  NCT04401995· Phase 2· Diwakar Davar· Source

• Terminated

  A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors

  NCT04442126· Phase 1/2· Numab Therapeutics AG· Source

• Completed

  Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

  NCT04370704· Phase 1/2· Incyte Corporation· Source

• Completed

  HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma

  NCT04369937· Phase 2· Dan Zandberg· Source

• Completed

  First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors

  NCT04417465· Phase 1· AbbVie· Source

Showing 50 of 80.

Conditions

Diseases this institution publishes on or runs trials for.

• Melanoma75 works · 69 trials
• Triple-negative breast cancer27 works · 15 trials
• Head and neck cancer24 works · 44 trials
• Metastatic breast cancer24 works · 13 trials
• Glioblastoma22 works · 18 trials
• Chronic lymphocytic leukaemia8 works · 10 trials